MOZITEC®
Tablet 12
registration number
47/20.2.6/1014
What MOZITEC® is and what it is used for
Mozitec® is indicated for the prophylaxis of drug-sensitive and drug-resistant Plasmodium falciparum malaria. Official guidelines and local information on the prevalence of resistance to antimalarial medicines should be taken into consideration.
dosage
Prophylaxis: Prophylaxis should start 1 to 2 days before entering a malaria-endemic area and be continued daily until 7 days after leaving the area.
Dosage in adults: One Mozitec® tablet daily.
Dosage in the elderly: No dosage adjustments are needed in the elderly (see pharmacokinetics).
Dosage in hepatic impairment: No dosage adjustments are needed in patients with mild to moderate hepatic impairment. No studies have been conducted in patients with severe hepatic impairment.
Dosage in renal impairment: No dosage adjustments are needed in patients with mild to moderate renal impairment. For prophylaxis of P. falciparum malaria in patients with severe renal impairment (see CONTRAINDICATIONS on approved Professional and Patient Information Leafets).
how to take
The daily dose should be taken with food or milk at the same time each day. Should vomiting occur within 1 hour of dosing, a repeat dose should be taken.
What MOZITEC® contains
Each film-coated tablet contains 250 mg atovaquone and 100 mg proguanil hydrochloride.
other ingredients
Microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, poloxamer 188, povidone, colloidal silicon dioxide, magnesium stearate and opadry brown (hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, ferric oxide).
Therapeutic classification
A 20.2.6 Medicines against protozoa.